Chimeric Therapeutics is trading 10% down now at A$0.04 after no confirmed company-specific catalyst was identified for August 14, 2026.
- Recent financing and R&D-tax funding announcements predated the decline, including A$1.62 million in R&D-tax funding announced August 6, 2026.
- The broader market was broadly unchanged, so available evidence does not support a global-market explanation.
- The move remains unattributed and may reflect selling pressure or limited liquidity.